Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 2013. The report details a specific share repurchase transaction executed on October 7, 2013, authorized by shareholders at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,443,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,571.50 pence per share; lowest price paid was 1,543.50 pence per share.
- Treasury Holdings (Settled): 487,264,412 shares (9.08% of total issued share capital).
- Treasury Holdings (Including Unsettled): 491,572,412 shares (10.08% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,878,704,711 shares.
Material Changes
The primary material change is the increase in the Company's treasury share holdings following the October 7 transaction. The total voting rights held in treasury now represent 10.08% of the Company's current total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in treasury (487,264,412 settled) against the latest quarterly reports.
- Confirm the percentage of total voting rights held in treasury (10.08% including unsettled shares) for disclosure threshold calculations.
- Check the number of shares in issue excluding treasury (4,878,704,711) for EPS denominator calculations.
- Review the price range paid (1,543.50 to 1,571.50 pence) to assess the cost of capital return relative to market price at the time.